Macrophage cholesterol efflux and the active domains of serum amyloid A 2.1

Journal of Lipid Research

Volumn 44, Issue 12, 2003, Pages 2257-2269

  Kisilevskyl, Robert ^a,b,c   Tam, Shui Pang ^b,c  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Acyl CoA:cholesterol acyltransferase; In vivo; Macrophages

Indexed keywords

CARRIER PROTEIN; CHLOROQUINE; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTERASE; HIGH DENSITY LIPOPROTEIN; LIPOSOME; SERUM AMYLOID A; SERUM AMYLOID A 1.1; SERUM AMYLOID A 2.1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REPRESSION; FEMALE; LIPID TRANSPORT; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN;

ANIMALS; APOLIPOPROTEINS; BETA-CYCLODEXTRINS; BINDING SITES; BIOLOGICAL TRANSPORT; CELLS, CULTURED; CHLOROQUINE; CHOLESTEROL; CHOLESTEROL, HDL; CYCLIC AMP; CYCLODEXTRINS; FEMALE; LIPOSOMES; MACROPHAGES; MICE; PROTEIN STRUCTURE, TERTIARY; SERUM AMYLOID A PROTEIN; STEROL O-ACYLTRANSFERASE;

EID: 0347753241     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M300133-JLR200     Document Type: Article

References (59)

1. Ness, G. C., and C. M. Chambers. 2000. Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Proc. Soc. Exp. Biol. Med. 224: 8-19.
2. Blumenthal, R. S. 2000. Statins: effective antiatherosclerotic therapy. Am. Heart J. 139: 577-583.
3. Linton, M. F., and S. Fazio. 2001. Class A scavenger receptors, macrophages, and atherosclerosis. Curr. Opin. Lipidol. 12: 489-495.
4. Krieger, M., and J. Herz. 1994. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu. Rev. Biochem. 63: 601-637.
5. Chang, T. Y., C. C. Chang, S. Lin, C. Yu, B. L. Li, and A. Miyazaki. 2001. Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2. Curr. Opin. Lipidol. 12: 289-296.
6. Rudel, L. L., R. G. Lee, and T. L. Cockman. 2001. Acyl-coenzyme A:cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis. Curr. Opin. Lipidol. 12: 121-127.
7. St. Clair, R. W., P. G. Yancey, and M. A. Leight. 1995. Macrophage cholesterol balance: a potential site of genetic control of susceptibility to atherosclerosis. Ann. N. Y. Acad. Sci. 748: 264-275.
8. Oram, J. F. 2002. ATP-binding cassette transporter A1 and cholesterol trafficking. Curr. Opin. Lipidol. 13: 373-381.
9. Schmitz, G., and W. Drobnik. 2002. ATP-binding cassette transporters in macrophages: promising drug targets for treatment of cardiovascular disease. Curr. Opin. Investig. Drugs. 3: 853-858.
10. Macchia, T., R. Mancinelli, D. A. Barbini, F. Taggi, U. Avico, and A. Cantafora. 1991. Determination of membrane cholesterol in normal and pathological red blood cells. Clin. Chim. Acta. 199: 59-67.
11. Cooper, R. A. 1978. Influence of increased membrane cholesterol on membrane fluidity and cell function in human red blood cells. J. Supramol. Struct. 8: 413-430.
12. Tam, S. P., A. Flexman, J. Hulme, and R. Kisilevsky. 2002. Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A 2.1. J. Lipid Res. 43: 1410-1420.
13. Jensen, L. E., M. P. Hiney, D. C. Shields, C. M. Uhlar, A. J. Lindsay, and A. S. Whitehead. 1997. Acute phase proteins in salmonids: evolutionary, analyses and acute phase response. J. Immunol. 158: 384-392.
14. Santiago, P., J. L. Roig-Lopez, C. Santiago, and J. E. Garcia-Arraras. 2000. Serum amyloid A protein in an echinoderm: its primary structure and expression during intestinal regeneration in the sea cucumber Holothuria glaberrima. J. Exp. Zool. 288: 335-344.
15. Lowell, C. A., D. A. Potter, R. S. Stearman, and J. F. Morrow. 1986. Structure of the murine serum amyloid A gene family. Gene conversion. J. Biol. Chem. 261: 8442-8452.
16. Rokita, H., T. Shirahama, A. S. Cohen, R. L. Meek, E. P. Benditt, and J. D. Sipe. 1987. Differential expression of the amyloid SAA gene in liver and peritoneal macrophages of mice undergoing dissimilar inflammatory episodes. J. Immunol. 139: 3849-3853.
17. Benditt, E. P., and R. L. Meek. 1989. Expression of the third member of the serum amyloid A gene family in mouse adipocytes. J. Exp. Med. 169: 1841-1846.
18. Sipe, J. D., and P. Westermark. 1999. Revised nomenclature for serum amyloid A (SAA). Amyloid. 6: 67-70.
19. Whitehead, A. S., M. C. Debeer, D. M. Steel, M. Rits, J. M. Lelias, W. S. Lane, and F. C. deBeer. 1992. Identification of novel members of the serum amyloid-A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J. Biol. Chem. 267: 3862-3867.
20. Debeer, M. C., M. S. Kindy, W. S. Lane, and F. C. deBeer. 1994. Mouse serum amyloid A protein (SAA(5)) structure and expression. J. Biol. Chem. 269: 4661-4667.
21. Debeer, M. C., T. Yuan, M. S. Kindy, B. F. Asztalos, P. S. Roheim, and F. C. deBeer. 1995. Characterization of constitutive human serum amyloid A protein (SAA(4)) as an apolipoprotein. J. Lipid Res. 36: 526-534.
22. Kluve-Beckerman, B., M. L. Drumm, and M. D. Benson. 1991. Nonexpression of the human serum amyloid-A three (SAA3) gene. DNA Cell Biol. 10: 651-661.
23. Meek, R. L., N. Eriksen, and E. P. Benditt. 1992. Murine serum amyloid-A(3) is a high density apolipoprotein and is secreted by macrophages. Proc. Natl. Acad. Sci. USA. 89: 7949-7952.
24. Morrow, J. F., R. S. Stearman, C. G. Peltzman, and D. A. Potter. 1981. Induction of hepatic synthesis of serum amyloid A protein and actin. Proc. Natl. Acad. Sci. USA. 78: 4718-4722.
25. van der Westhuyzen, D. R., G. A. Coetzee, and F. C. de Beer. 1986. Serum amyloid A protein in plasma: characteristics of acute phase HDL. In Amyloidosis. J. Marrink and M. H. van Rijswijk, editors. Martinus Nijhoff, Dordrecht. 115-125.
26. Ely, S., R. Bonatesta, J. B. Anesin, M. Kindy, and R. Kisilevsky. 2001. The in vitro influence of serum amyloid A isoforms on enzymes that regulate the balance between esterified and un-esterified cholesterol. Amyloid. 8:169-181.
27. Allain, C. C., L. S. Poon, C. S. G. Chan, W. Richmond, and P. C. Fu. 1974. Enzymatic determination of total serum cholesterol. Clin. Chem. 20: 470-475.
28. Ancsin, J. B., and R. Kisilevsky. 1999. The heparin/heparan sulfate-binding site on apo-serum amyloid A: implications for the therapeutic intervention of amyloidosis. J. Biol. Chem. 274: 7172-7181.
29. Ancsin, J. B., and R. Kisilevsky. 1999. Laminin interactions with the apoproteins of acute-phase HDL: preliminary mapping of the laminin binding site on serum amyloid A. Amyloid. 6: 37-47.
30. Jonas, A., E. Kezdy, and J. H. Wald. 1989. Defined apolipoprotein A-I conformations in reconstituted high density lipoprotein discs. J. Biol. Chem. 264: 4818-4825.
31. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
32. Oram, J. F., A. J. Mendez, J. P. Slotte, and T. F. Johnson. 1991. High density lipoprotein apolipoproteins mediate removal of sterol from intracellular pools but not from plasma membranes of cholesterol-loaded fibroblasts. Arterioscler. Thromb. 11: 403-414.
33. Mendez, A. J., G. M. Anantharamaiah, J. P. Segrest, and J. F. Oram. 1994. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J. Clin. Invest. 94: 1698-1705.
34. Myer, B. M., P. S. Tietz, T. E. Tarara, and N. F. LaRusso. 1995. Dynamic measurements of the acute and chronic effects of lysosomotropic agents on hepatocyte lysosomal pH using flow cytometry. Hepatology. 22: 1519-1526.
35. Klempner, M. S., and B. Styrt. 1983. Alkalinizing thee intralysosomal pH inhibits degranulation of human neutrophils. J. Clin. Invest. 72: 1793-1800.
36. Goldstein, J. L., S. E. Dana, J. R. Faust, A. L. Beaudet, and M. S. Brown. 1975. Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease. J. Biol. Chem. 250:8487-8495.
37. Lin, G., and K. E. Bornfeldt. 2002. Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux. Biochem. Biophys. Res. Commun. 290: 663-669.
38. Oram, J. F., R. M. Lawn, M. R. Garvin, and D. P. Wade. 2000. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J. Biol. Chem. 275: 34508-34511.
39. Isersky, C., D. L. Page, P. Cuatrecasas, R. A. DeLillis, and G. G. Glenner. 1971. Murine amyloidosis: immunologic characterization of amyloid fibril protein. J. Immunol. 107: 1690-1698.
40. Husby, G., G. Marhaug, B. Dowton, K. Sletten, and J. D. Sipe. 1994. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid. 1: 118-137.
41. Husebekk, A., B. Skogen, and G. Husby. 1987. Characterization of amyloid proteins AA and SAA as apolipoproteins of high density lipoproteins (HDL). Displacement of SAA from the HDL-SAA complex by apoA-I and apoA-II. Scand. J. Immunol. 25: 375-382.
42. Hoffman, J. S., and E. P. Benditt. 1982. Secretion of serum amyloid protein and assembly of serum amyloid protein-rich high density lipoprotein in primary mouse hepatocyte culture. J. Biol. Chem. 257: 10518-10522.
43. Meek, R. L., J. S. Hoffman, and E. P. Benditt. 1986. Amyloidogenesis. One serum amyloid A isotype is selectively removed from the circulation. J. Exp. Med. 163: 499-510.
44. Husebekk, A., B. Skogen, G. Husby, and G. Marhaug. 1985. Transformation of amyloid precurser SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand. J. Immunol. 21: 283-287.
45. Tape, C., R. Tan, M. Nesheim, and R. Kisilevsky. 1988. Direct evidence for circulating apoSAA as the precursor of tissue AA amyloid deposits. Scand. J. Immunol. 28: 317-324.
46. Kisilevsky, R., and S. P. Tam. 2002. Serum amyloid A, cholesterol metabolism, and cardiovascular disease. Pediatr. Pathol. Mol. Med. 21: 291-305.
47. Kisilevsky, R. 1991. Serum amyloid-A (SAA), a protein without a function: some suggestions with reference to cholesterol metabolism. Med. Hypotheses. 35: 337-341.
48. Kisilevsky, R., E. Lindhorst, J. B. Ancsin, D. Young, and W. Bagshaw. 1996. Acute phase serum amyloid A (SAA) and cholesterol transport during acute inflammation: a hypothesis. Amyloid. 3: 252-260.
49. Lindhorst, E., D. Young, W. Bagshaw, M. Hyland, and R. Kisilevsky. 1997. Acute inflammation, acute phase serum amyloid A and cholesterol metabolism in the mouse. Biochim. Biophys. Acta. 1339: 143-154.
50. Clifton, P. M., A. M. Mackinnon, and P. J. Barter. 1985. Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J. Lipid Res. 26: 1389-1398.
51. Bausserman, L. L., A. Sadaniantz, A. L. Saritelli, V. L. Martin, A. M. Nugent, S. P. Sady, and P. N. Herbert. 1989. Time course of serum amyloid-A response in myocardial infarction. Clin. Chim. Acta. 184: 297-306.
52. Liuzzo, G., L. M. Biasucci, J. R. Gallimore, R. L. Grillo, A. G. Rebuzzi, M. B. Pepys, and A. Maseri. 1994. Prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 331: 417-424.
53. Ridker, P. M., N. Rifai, M. A. Pfeffer, F. M. Sacks, L. A. Moye, S. Goldman, G. C. Flaker, and E. Braunwald. 1998. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98: 839-844.
54. Rosenthal, C. J., and E. C. Franklin. 1975. Variation with age and disease of amyloid A protein-related serum component. J. Clin. Invest. 55: 746-753.
55. Jousilahti, P., V. Salomaa, V. Rasi, E. Vahtera, and T. Palosuo. 2001. The association of C-reactive protein, serum amyloid A and fibrinogen with prevalent coronary heart disease-baseline findings of the PAIS project. Atherosclerosis. 156: 451-456.
56. Van Lenten, B. J., S. Y. Hama, F. C. de Beer, D. M. Stafforini, T. M. McIntyre, S. M. Prescott, B. N. La Du, A. M. Fogelman, and M. Navab. 1995. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96:2758-2767.
57. Steinmetz, A., G. Hocke, R. Saile, P. Puchois, and J. C. Fruchart. 1989. Influence of serum amyloid-A on cholesterol esterification in human plasma. Biochim. Biophys. Acta. 1006:173-178.
58. Kumon, Y., Y. Nakauchi, K. Kidawara, M. Fukushima, S. Kobayashi, Y. Ikeda, T. Suehiro, K. Hashimoto, and J. D. Sipe. 1998. A longitudinal analysis of alteration in lecithin-cholesterol acyltransferase and paraoxonase activities following laparoscopic cholecystectomy relative to other parameters of HDL function and the acute phase response. Scand. J. Immunol. 48: 419-424.
59. Gotlieb, A. I., E. P. Benditt, and S. M. Schwartz. 1999. Blood vessels. In Pathology. E. Rubin and J. L. Farber, editors. Lippincott-Raven, Philadelphia, New York. 481-530.